PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics has announced it will validate the NOVAprep® liquid-based cytology platform with Abbott’s RealTime High Risk HPV (Human papillomavirus) assay.
The purpose of this collaboration is to validate the use of Novacyt’s proprietary NOVAprep® cytology medium when used in cervical cancer screening with Abbott’s molecular HPV assay. HPV testing provides important information about whether a patient has an HPV infection with any of the 14 high-risk HPV types and this information, along with the result of the PAP smear, can be useful in managing patients with inconclusive results.
The results from the validation study are expected to be published within the upcoming months to show the performance of the NOVAprep® technology compared to the storage vials used by other competitor liquid based cytology systems. The results could demonstrate that the quality of the cervical cancer sample preparation and storage of preserved cells are critical to the performance of HPV testing.
Graham Mullis, Group CEO of Novacyt, commented, "We believe there is an emerging opportunity for the NOVAprep® vial and medium to be used in cervical cancer screening sample preparation, cell storage and testing for both HPV and cytology testing. There is a critical need for a good quality sample preparation and storage system which can be universally used in the market for HPV testing across multiple HPV testing platforms. We see the collaboration with Abbott therefore as an example of major expansion opportunities that exist for Novacyt to develop other potential strategic partnerships with HPV platform providers.”
- Ends –
About Novacyt Group
The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NOVAprep® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.
For more information please refer to the website: www.novacyt.com